Stereotaxis to Present at Upcoming Investor Conferences
Stereotaxis (NYSE: STXS), a leader in surgical robotics for minimally invasive endovascular intervention, has announced its participation in two upcoming investor conferences. David Fischel, Chairman and CEO, will represent the company at both events:
1. H.C. Wainwright 26th Annual Global Investment Conference on September 11th, 2024, where he will present a company overview at 12:30 pm EST and be available for one-on-one meetings.
2. Lake Street 8th Annual Best Ideas Growth Conference on September 12, 2024, where he will be available for one-on-one meetings.
Fischel expressed appreciation for the opportunity to share Stereotaxis' ongoing technological, commercial, and strategic progress with investors. Interested parties can arrange meetings through conference registration.
Stereotaxis (NYSE: STXS), leader nella robotica chirurgica per interventi endovascolari minimamente invasivi, ha annunciato la sua partecipazione a due prossime conferenze per investitori. David Fischel, Presidente e CEO, rappresenterà l'azienda in entrambi gli eventi:
1. 26ª Conferenza Globale Annuale sugli Investimenti di H.C. Wainwright il 11 settembre 2024, dove presenterà una panoramica dell'azienda alle 12:30 EST e sarà disponibile per incontri individuali.
2. 8ª Conferenza Annuale di Lake Street sulle Migliori Idee di Crescita il 12 settembre 2024, dove sarà disponibile per incontri individuali.
Fischel ha espresso gratitudine per l'opportunità di condividere i progressi tecnologici, commerciali e strategici di Stereotaxis con gli investitori. Le parti interessate possono organizzare incontri tramite la registrazione alla conferenza.
Stereotaxis (NYSE: STXS), líder en robótica quirúrgica para intervenciones endovasculares mínimamente invasivas, ha anunciado su participación en dos próximas conferencias para inversores. David Fischel, Presidente y CEO, representará a la empresa en ambos eventos:
1. 26ª Conferencia Anual Global de Inversiones de H.C. Wainwright el 11 de septiembre de 2024, donde presentará una visión general de la empresa a las 12:30 pm EST y estará disponible para reuniones individuales.
2. 8ª Conferencia Anual de Lake Street sobre las Mejores Ideas de Crecimiento el 12 de septiembre de 2024, donde estará disponible para reuniones individuales.
Fischel expresó su agradecimiento por la oportunidad de compartir el progreso tecnológico, comercial y estratégico de Stereotaxis con los inversores. Las partes interesadas pueden concertar reuniones a través del registro para la conferencia.
스테레오택시스(Stereotaxis, NYSE: STXS)는 최소 침습적인 혈관 내 개입을 위한 외과 로봇 기술의 선두주자로서, 다가오는 두 개의 투자자 회의에 참여한다고 발표했습니다. 데이비드 피셸 CEO이 두 행사에 회사를 대표합니다:
1. H.C. Wainwright 제26회 연례 글로벌 투자 회의가 2024년 9월 11일에 열리며, 이 회의에서 오후 12시 30분 EST에 회사 개요를 발표하고 일대일 미팅을 진행할 예정입니다.
2. Lake Street 제8회 연례 최고의 성장 아이디어 회의가 2024년 9월 12일에 열리며, 이 회의에서 일대일 미팅을 진행할 예정입니다.
피셸은 투자자들과 스테레오택시스의 지속적인 기술적, 상업적 및 전략적 발전을 공유할 기회에 감사함을 표했습니다. 관심 있는 분들은 회의 등록을 통해 미팅을 조정할 수 있습니다.
Stereotaxis (NYSE: STXS), un leader dans la robotique chirurgicale pour les interventions endovasculaires peu invasives, a annoncé sa participation à deux conférences pour investisseurs à venir. David Fischel, Président-directeur général, représentera l'entreprise lors de ces deux événements :
1. 26ème Conférence Annuelle Globale sur les Investissements de H.C. Wainwright le 11 septembre 2024, où il présentera un aperçu de l'entreprise à 12h30 EST et sera disponible pour des réunions individuelles.
2. 8ème Conférence Annuelle de Lake Street sur les Meilleures Idées de Croissance le 12 septembre 2024, où il sera également disponible pour des réunions individuelles.
Fischel a exprimé sa gratitude pour l'opportunité de partager les progrès technologiques, commerciaux et stratégiques de Stereotaxis avec les investisseurs. Les parties intéressées peuvent organiser des réunions via l'inscription à la conférence.
Stereotaxis (NYSE: STXS), ein führendes Unternehmen in der chirurgischen Robotik für minimalinvasive endovasale Eingriffe, hat seine Teilnahme an zwei bevorstehenden Investorenkonferenzen bekannt gegeben. David Fischel, Vorsitzender und CEO, wird das Unternehmen bei beiden Veranstaltungen vertreten:
1. 26. Jährliche Globale Investorenkonferenz von H.C. Wainwright am 11. September 2024, wo er um 12:30 Uhr EST eine Unternehmensübersicht präsentieren und für Einzelgespräche zur Verfügung stehen wird.
2. 8. Jährliche Best Ideas Growth Conference von Lake Street am 12. September 2024, wo er für Einzelgespräche zur Verfügung stehen wird.
Fischel äußerte seine Wertschätzung für die Möglichkeit, den Investoren die fortlaufenden technologischen, kommerziellen und strategischen Fortschritte von Stereotaxis zu präsentieren. Interessierte Parteien können über die Registrierung zur Konferenz Meetings vereinbaren.
- None.
- None.
ST. LOUIS, Sept. 09, 2024 (GLOBE NEWSWIRE) -- Stereotaxis (NYSE: STXS), a pioneer and global leader in surgical robotics for minimally invasive endovascular intervention, today announced that David Fischel, Chairman and CEO, will represent Stereotaxis at two upcoming investor conferences.
- H.C. Wainwright 26th Annual Global Investment Conference
Mr. Fischel will present an overview of Stereotaxis business on Wednesday, September 11th, 2024, at 12:30 pm EST and will be available that same day for one-on-one meetings.
- Lake Street 8th Annual Best Ideas Growth Conference
Mr. Fischel will be available for one-on-one meetings on Thursday, September 12, 2024.
“We appreciate the opportunity to participate in these conferences and look forward to sharing Stereotaxis' continued technological, commercial and strategic progress,” says Mr. Fischel. One-on-one meetings with Mr. Fischel can be arranged through registration with the conferences.
About Stereotaxis
Stereotaxis (NYSE: STXS) is a pioneer and global leader in innovative surgical robotics for minimally invasive endovascular intervention. Its mission is the discovery, development and delivery of robotic systems, instruments, and information solutions for the interventional laboratory. These innovations help physicians provide unsurpassed patient care with robotic precision and safety, expand access to minimally invasive therapy, and enhance the productivity, connectivity, and intelligence in the operating room. Stereotaxis technology has been used to treat over 100,000 patients across the United States, Europe, Asia, and elsewhere. For more information, please visit www.stereotaxis.com.
This press release includes statements that may constitute "forward-looking" statements, usually containing the words "believe”, "estimate”, "project”, "expect" or similar expressions. Forward-looking statements inherently involve risks and uncertainties that could cause actual results to differ materially. Factors that would cause or contribute to such differences include, but are not limited to, the Company's ability to manage expenses at sustainable levels, acceptance of the Company's products in the marketplace, the effect of global economic conditions on the ability and willingness of customers to purchase its technology, competitive factors, changes resulting from healthcare policy, dependence upon third-party vendors, timing of regulatory approvals, the impact of pandemics or other disasters, and statements relating to our recent acquisition of APT, including any benefits expected from the acquisition, and other risks discussed in the Company's periodic and other filings with the Securities and Exchange Commission. By making these forward-looking statements, the Company undertakes no obligation to update these statements for revisions or changes after the date of this release. There can be no assurance that the Company will recognize revenue related to its purchase orders and other commitments because some of these purchase orders and other commitments are subject to contingencies that are outside of the Company's control and may be revised, modified, delayed, or canceled.
Stereotaxis Contacts:
David L. Fischel
Chairman and Chief Executive Officer
Kimberly Peery
Chief Financial Officer
314-678-6100
Investors@Stereotaxis.com
FAQ
When is Stereotaxis (STXS) presenting at the H.C. Wainwright Global Investment Conference?
Which investor conferences is Stereotaxis (STXS) attending in September 2024?
Who will represent Stereotaxis (STXS) at the upcoming investor conferences?
What type of meetings will be available at the Lake Street Conference for Stereotaxis (STXS)?
How can investors arrange meetings with Stereotaxis (STXS) at these conferences?
